Should I buy or sell Day One Biopharmaceuticals stock right now?

7 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Day One Biopharmaceuticals in the last year. There are currently 1 sell rating, 1 hold rating and 5 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "moderate buy" DAWN shares. View DAWN analyst ratings or view top-rated stocks .

What is Day One Biopharmaceuticals' stock price target for 2024?

7 analysts have issued 12 month target prices for Day One Biopharmaceuticals' stock. Their DAWN share price targets range from $34.00 to $50.00. On average, they predict the company's stock price to reach $40.60 in the next twelve months. This suggests a possible upside of 172.1% from the stock's current price. View analysts price targets for DAWN or view top-rated stocks among Wall Street analysts .

How have DAWN shares performed in 2024?

Day One Biopharmaceuticals' stock was trading at $14.60 at the beginning of the year. Since then, DAWN stock has increased by 2.2% and is now trading at $14.92. View the best growth stocks for 2024 here .

Are investors shorting Day One Biopharmaceuticals?

Day One Biopharmaceuticals saw a drop in short interest during the month of March. As of March 31st, there was short interest totaling 8,980,000 shares, a drop of 6.6% from the March 15th total of 9,610,000 shares. Based on an average daily trading volume, of 619,200 shares, the days-to-cover ratio is currently 14.5 days. Currently, 15.2% of the shares of the company are short sold. View Day One Biopharmaceuticals' Short Interest .

When is Day One Biopharmaceuticals' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Monday, May 6th 2024. View our DAWN earnings forecast .

How were Day One Biopharmaceuticals' earnings last quarter?

Day One Biopharmaceuticals, Inc. (NASDAQ:DAWN) posted its earnings results on Monday, February, 26th. The company reported ($0.64) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.57) by $0.07.

What ETFs hold Day One Biopharmaceuticals' stock?

ETFs with the largest weight of Day One Biopharmaceuticals (NASDAQ:DAWN) stock in their portfolio include Simplify Propel Opportunities ETF (SURI) , Loncar China Biopharma ETF (CHNA) and Range Cancer Therapeutics ETF (CNCR) . ALPS Medical Breakthroughs ETF (SBIO) .

When did Day One Biopharmaceuticals IPO?

Day One Biopharmaceuticals (DAWN) raised $126 million in an initial public offering on Thursday, May 27th 2021. The company issued 8,400,000 shares at $14.00-$16.00 per share. J.P. Morgan, Cowen and Piper Sandler acted as the underwriters for the IPO and Wedbush PacGrow was co-manager.

Who are Day One Biopharmaceuticals' major shareholders?

Day One Biopharmaceuticals' stock is owned by a number of retail and institutional investors. Top institutional investors include Hennion & Walsh Asset Management Inc. (0.07%). Insiders that own company stock include Adam Dubow, Ai Day1 Llc, Charles N York II, Jeremy Bender, Julie Papanek Grant, Michael Gladstone, Papanek Julie Grant , Pharmaceutical Co Ltd Takeda, Samuel C Blackman , Venture Fund Xi LP Atlas and Xi LP Canaan. View institutional ownership trends .

How do I buy shares of Day One Biopharmaceuticals?

Shares of DAWN stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here .

NASDAQ:DAWN

Day One Biopharmaceuticals (DAWN) Stock Price, News & Analysis

→ Strange new buyer driving up gold (From Stansberry Research) (Ad)

Free DAWN Stock Alerts

$14.92

-0.83 (-5.27%)

(As of 03:39 PM ET)

Compare

Today's Range: $14.44
▼
$16.02
50-Day Range: $13.77
▼
$17.46
52-Week Range: $9.67
▼
$17.85

Volume: 1.03 million shs
Average Volume: 639,638 shs
Market Capitalization: $1.30 billion

P/E Ratio: N/A
Dividend Yield: N/A
Price Target: $40.60

Get Day One Biopharmaceuticals alerts:

Day One Biopharmaceuticals MarketRank™ Stock Analysis

Analyst Rating: Moderate Buy
2.57 Rating Score
Upside/Downside: 172.1% Upside
$40.60 Price Target
Short Interest: Bearish
15.24% of Float Sold Short
Dividend Strength: N/A
Sustainability: N/A
News Sentiment: 0.89
Based on 8 Articles This Week
Insider Trading: Selling Shares
$722,960 Sold Last Quarter
Proj. Earnings Growth: Growing
From ($2.66) to ($2.12) Per Share

Overall MarketRank^™

New Rank-Based ScoringMarketRank^™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.

2.08 out of 5 stars

Medical Sector

552nd out of 918 stocks

Pharmaceutical Preparations Industry

248th out of 417 stocks

3.3

Analyst's Opinion

Consensus Rating
Day One Biopharmaceuticals has received a consensus rating of Moderate Buy. The company's average rating score is 2.57, and is based on 5 buy ratings, 1 hold rating, and 1 sell rating.
Amount of Analyst Coverage
Day One Biopharmaceuticals has only been the subject of 3 research reports in the past 90 days.

2.0

Short Interest

Percentage of Shares Shorted
15.24% of the float of Day One Biopharmaceuticals has been sold short.
Short Interest Ratio / Days to Cover
Day One Biopharmaceuticals has a short interest ratio ("days to cover") of 14.5, which indicates bearish sentiment.
Change versus previous month
Short interest in Day One Biopharmaceuticals has recently decreased by 6.56%, indicating that investor sentiment is improving significantly.

0.0

Dividend Strength

Dividend Yield
Day One Biopharmaceuticals does not currently pay a dividend.
Dividend Growth
Day One Biopharmaceuticals does not have a long track record of dividend growth.

N/A

Sustainability and ESG

Overall ESG (Environmental, Social, and Governance) Score
There is no current Upright™ data available for DAWN.

2.7

News and Social Media Coverage

News Sentiment
Day One Biopharmaceuticals has a news sentiment score of 0.89. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.52 average news sentiment score of Medical companies.
News Coverage This Week
MarketBeat has tracked 8 news articles for Day One Biopharmaceuticals this week, compared to 2 articles on an average week.
Search Interest
Only 1 people have searched for DAWN on MarketBeat in the last 30 days. This is a decrease of -67% compared to the previous 30 days.
MarketBeat Follows
Only 3 people have added Day One Biopharmaceuticals to their MarketBeat watchlist in the last 30 days. This is a decrease of -50% compared to the previous 30 days.

2.5

Company Ownership

Insider Buying vs. Insider Selling
In the past three months, Day One Biopharmaceuticals insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $722,960.00 in company stock.
Percentage Held by Insiders
Only 8.40% of the stock of Day One Biopharmaceuticals is held by insiders.
Percentage Held by Institutions
87.95% of the stock of Day One Biopharmaceuticals is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

0.6

Earnings and Valuation

Earnings Growth
Earnings for Day One Biopharmaceuticals are expected to grow in the coming year, from ($2.66) to ($2.12) per share.
Price to Earnings Ratio vs. the Market
The P/E ratio of Day One Biopharmaceuticals is -6.27, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Earnings Ratio vs. Sector
The P/E ratio of Day One Biopharmaceuticals is -6.27, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Book Value per Share Ratio
Day One Biopharmaceuticals has a P/B Ratio of 3.75. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.

See Top Rated MarketRank™ Stocks Here

Ad Stansberry Research

Strange new buyer driving up gold

One Wall Street trader just made a big new gold prediction: "Pay attention to physical demand for gold... the interest seen over the last week has been unprecedented."

But there's a much better move you can make to get in front of these big moves today.

About Day One Biopharmaceuticals Stock (NASDAQ:DAWN)

Day One Biopharmaceuticals, Inc., a clinical-stage biopharmaceutical company, develops and commercializes targeted therapies for patients with genomically defined cancers. Its lead product candidate is tovorafenib, an oral brain-penetrant type II pan-rapidly accelerated fibrosarcoma kinase inhibitor that is in Phase II clinical trial for pediatric patients with relapsed/ refractory low-grade glioma. The company is also developing Pimasertib, an oral small molecule inhibitor of mitogen-activated protein kinase kinases 1 and 2. Day One Biopharmaceuticals, Inc. was incorporated in 2018 and is headquartered in Brisbane, California.

DAWN Stock Price History

30 days | 90 days | 365 days | Advanced Chart

DAWN Stock News Headlines

March 27, 2024 | insidertrades.com

Day One Biopharmaceuticals, Inc. (NASDAQ:DAWN) Insider Samuel C. Blackman Sells 10,000 Shares

April 18, 2024 | americanbankingnews.com

Short Interest in Day One Biopharmaceuticals, Inc. (NASDAQ:DAWN) Declines By 6.6%

April 19, 2024 | Gold Safe Exchange (Ad)

The “Perfect Storm” for Gold

Gold has already reached all-time highs, and experts believe it's not slowing down any time soon. In fact, some analysts predict a $7,000 price tag by 2025.

April 17, 2024 | americanbankingnews.com

Day One Biopharmaceuticals, Inc. (NASDAQ:DAWN) Given Consensus Rating of "Moderate Buy" by Brokerages

April 16, 2024 | markets.businessinsider.com

Analysts Are Bullish on These Healthcare Stocks: OptimizeRx (OPRX), Day One Biopharmaceuticals (DAWN)

April 10, 2024 | markets.businessinsider.com

Buy Rating on Day One Biopharmaceuticals Ahead of Tovorafenib PDUFA Date and Potential for Market Disruption

April 4, 2024 | morningstar.com

Day One Biopharmaceuticals Inc DAWN

March 26, 2024 | markets.businessinsider.com

Analysts’ Opinions Are Mixed on These Healthcare Stocks: Day One Biopharmaceuticals (DAWN), BioMarin Pharmaceutical (BMRN) and Argenx Se (ARGX)

April 19, 2024 | Gold Safe Exchange (Ad)

The “Perfect Storm” for Gold

Gold has already reached all-time highs, and experts believe it's not slowing down any time soon. In fact, some analysts predict a $7,000 price tag by 2025.

March 17, 2024 | finance.yahoo.com

DAWN Jul 2024 17.500 call

March 15, 2024 | finance.yahoo.com

Companies Like Day One Biopharmaceuticals (NASDAQ:DAWN) Are In A Position To Invest In Growth

February 29, 2024 | markets.businessinsider.com

Analysts Are Bullish on Top Healthcare Stocks: Day One Biopharmaceuticals (DAWN), Crinetics Pharmaceuticals (CRNX)

February 28, 2024 | markets.businessinsider.com

Buy Rating Reaffirmed for Day One Biopharmaceuticals Amid Tovorafenib’s Promising Prospects and Financial Stability

February 28, 2024 | finance.yahoo.com

Day One Biopharmaceuticals Inc (DAWN) Reports Q4 and Full Year 2023 Financial Results

February 27, 2024 | finanznachrichten.de

Day One Biopharmaceuticals, Inc.: Day One Reports Fourth Quarter and Full Year 2023 Financial Results and Corporate Progress

February 27, 2024 | edition.cnn.com

Day One Biopharmaceuticals, Inc.

February 26, 2024 | globenewswire.com

Day One Reports Fourth Quarter and Full Year 2023 Financial Results and Corporate Progress

February 6, 2024 | benzinga.com

Day One Biopharmaceutical Stock (NASDAQ:DAWN), Short Interest Report

February 1, 2024 | seekingalpha.com

Navigating Day One Biopharmaceuticals' Financial Health And Clinical Prospects

December 19, 2023 | finance.yahoo.com

Day One to Present at the 42nd Annual J.P. Morgan Healthcare Conference

November 27, 2023 | finance.yahoo.com

Milei to Send ‘Shock’ Package to Argentina’s Congress on Day One

November 14, 2023 | finance.yahoo.com

Day One to Participate in the Piper Sandler 35th Annual Healthcare Conference

November 9, 2023 | morningstar.com

Day One Biopharmaceuticals Inc

November 8, 2023 | markets.businessinsider.com

Day One Biopharmaceuticals: High Confidence in Tovorafenib’s FDA Approval and Promising Expansion Strategy

November 6, 2023 | msn.com

Day One Biopharmaceuticals GAAP EPS of -$0.54

November 6, 2023 | finance.yahoo.com

Day One Reports Third Quarter 2023 Financial Results and Corporate Progress

November 6, 2023 | finance.yahoo.com

Day One Biopharmaceuticals Inc (DAWN) Reports Q3 2023 Financial Results and Corporate Progress

See More Headlines

Receive DAWN Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Day One Biopharmaceuticals and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings: 2/26/2024
Today: 4/19/2024
Next Earnings (Estimated): 5/06/2024
Fiscal Year End: 12/31/2024

Get Stock Alerts

Industry, Sector and Symbol

Stock Exchange: NASDAQ
Sector: Medical
Industry: Pharmaceutical preparations
Sub-Industry: N/A
Current Symbol: NASDAQ:DAWN
CUSIP: N/A
CIK: 1845337
Web: dayonebio.com
Phone: 650-484-0899
Fax: N/A
Employees: 155
Year Founded: N/A

Price Target and Rating

Average Stock Price Target: $40.60
High Stock Price Target: $50.00
Low Stock Price Target: $34.00
Potential Upside/Downside: +157.8%
Consensus Rating: Moderate Buy
Rating Score (0-4): 2.57
Research Coverage: 7 Analysts

Profitability

EPS (Most Recent Fiscal Year): ($2.38)
Trailing P/E Ratio: N/A
Forward P/E Ratio: N/A
P/E Growth: N/A
Net Income: $-188,920,000.00
Net Margins: N/A
Pretax Margin: N/A
Return on Equity: -51.67%
Return on Assets: -48.30%

Debt

Debt-to-Equity Ratio: N/A
Current Ratio: 12.72
Quick Ratio: 12.72

Sales & Book Value

Annual Sales: N/A
Price / Sales: N/A
Cash Flow: N/A
Price / Cash Flow: N/A
Book Value: $3.98 per share
Price / Book: 3.96

Miscellaneous

Outstanding Shares: 87,380,000
Free Float: 80,037,000
Market Cap: $1.38 billion
Optionable: Optionable
Beta: -1.48

7 Stocks to Buy And Hold Forever

Click the link below and we'll send you MarketBeat's list of seven stocks and why their long-term outlooks are very promising.

Get This Free Report

Key Executives

Dr. Jeremy Bender M.B.A. (Age 53)
Ph.D., CEO, President & Director
Comp: $900k
Dr. Samuel C. Blackman M.D. (Age 55)
Ph.D., Co-Founder and Head of R&D
Comp: $651k
Mr. Charles N. York II (Age 47)
COO, CFO & Secretary
Comp: $715k
Dr. Mike Preigh Ph.D.
Chief of Technology Operations
Mr. Adam Dubow (Age 57)
General Counsel
Ms. Jaa Roberson
Chief People Officer
Dr. Davy Chiodin Ph.D.
Pharm.D., Chief Development Officer
Ms. Lauren Merendino M.B.A. (Age 48)
Chief Commercial Officer
Dr. Elly Barry M.D.
Chief Medical Officer

Key Competitors

View All Competitors

Insiders & Institutions

View All Insider Transactions
View All Institutional Transactions

DAWN Stock Analysis - Frequently Asked Questions

Should I buy or sell Day One Biopharmaceuticals stock right now?: 7 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Day One Biopharmaceuticals in the last year. There are currently 1 sell rating, 1 hold rating and 5 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "moderate buy" DAWN shares.
View DAWN analyst ratings or view top-rated stocks.
What is Day One Biopharmaceuticals' stock price target for 2024?: 7 analysts have issued 12 month target prices for Day One Biopharmaceuticals' stock. Their DAWN share price targets range from $34.00 to $50.00. On average, they predict the company's stock price to reach $40.60 in the next twelve months. This suggests a possible upside of 172.1% from the stock's current price.
View analysts price targets for DAWN or view top-rated stocks among Wall Street analysts.
How have DAWN shares performed in 2024?: Day One Biopharmaceuticals' stock was trading at $14.60 at the beginning of the year. Since then, DAWN stock has increased by 2.2% and is now trading at $14.92.
View the best growth stocks for 2024 here.
Are investors shorting Day One Biopharmaceuticals?: Day One Biopharmaceuticals saw a drop in short interest during the month of March. As of March 31st, there was short interest totaling 8,980,000 shares, a drop of 6.6% from the March 15th total of 9,610,000 shares. Based on an average daily trading volume, of 619,200 shares, the days-to-cover ratio is currently 14.5 days. Currently, 15.2% of the shares of the company are short sold.
View Day One Biopharmaceuticals' Short Interest.
When is Day One Biopharmaceuticals' next earnings date?: The company is scheduled to release its next quarterly earnings announcement on Monday, May 6th 2024.
View our DAWN earnings forecast.
How were Day One Biopharmaceuticals' earnings last quarter?: Day One Biopharmaceuticals, Inc. (NASDAQ:DAWN) posted its earnings results on Monday, February, 26th. The company reported ($0.64) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.57) by $0.07.

What ETFs hold Day One Biopharmaceuticals' stock?: ETFs with the largest weight of Day One Biopharmaceuticals (NASDAQ:DAWN) stock in their portfolio include Simplify Propel Opportunities ETF (SURI), Loncar China Biopharma ETF (CHNA) and Range Cancer Therapeutics ETF (CNCR).ALPS Medical Breakthroughs ETF (SBIO).
When did Day One Biopharmaceuticals IPO?: Day One Biopharmaceuticals (DAWN) raised $126 million in an initial public offering on Thursday, May 27th 2021. The company issued 8,400,000 shares at $14.00-$16.00 per share. J.P. Morgan, Cowen and Piper Sandler acted as the underwriters for the IPO and Wedbush PacGrow was co-manager.
Who are Day One Biopharmaceuticals' major shareholders?: Day One Biopharmaceuticals' stock is owned by a number of retail and institutional investors. Top institutional investors include Hennion & Walsh Asset Management Inc. (0.07%). Insiders that own company stock include Adam Dubow, Ai Day1 Llc, Charles N York II, Jeremy Bender, Julie Papanek Grant, Michael Gladstone, Papanek Julie Grant, Pharmaceutical Co Ltd Takeda, Samuel C Blackman, Venture Fund Xi LP Atlas and Xi LP Canaan.
View institutional ownership trends.
How do I buy shares of Day One Biopharmaceuticals?: Shares of DAWN stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

This page (NASDAQ:DAWN) was last updated on 4/19/2024 by MarketBeat.com Staff

From Our Partners

Get 30 Days of MarketBeat All Access Free

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your 30-Day Free Trial